← All trials
NCT06351020
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 24, 2024
- Primary completion
- Aug 10, 2026
- Completion date
- Dec 15, 2026
- First posted
- Apr 8, 2024
- Last posted
- Jul 1, 2024
- Enrollment
- 375
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- LaNova Medicines LimitedLead sponsor
- Huazhong University of Science and TechnologyOfficial
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.